CSL Ltd
Company Profile
Business description
CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world’s second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
Contact
655 Elizabeth Street
MelbourneVIC3000
AUST: +61 393891911
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
29,904
CSL Ltd News & Analysis
stocks
Weekly Earnings Wrap: CBA, CSL, MQG and more
markets
Market Minute: Japanese markets react strongly; AI uncertainty expected
stocks
ASX healthcare giant remains well positioned despite share slump
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,430.60 | 80.60 | 0.86% |
| CAC 40 | 8,378.50 | 202.25 | -2.36% |
| DAX 40 | 24,623.51 | 660.75 | -2.61% |
| Dow JONES (US) | 48,807.57 | 170.35 | -0.35% |
| FTSE 100 | 10,760.17 | 150.38 | -1.38% |
| HKSE | 26,059.85 | 570.69 | -2.14% |
| NASDAQ | 22,628.80 | 39.41 | -0.17% |
| Nikkei 225 | 58,057.24 | 793.03 | -1.35% |
| NZX 50 Index | 13,656.65 | 66.32 | -0.48% |
| S&P 500 | 6,856.47 | 22.41 | -0.33% |
| S&P/ASX 200 | 9,200.90 | 81.20 | 0.89% |
| SSE Composite Index | 4,182.59 | 19.71 | 0.47% |